pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

4,085 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1887Endpoints1461Fierce Biotech777BioSpace765BioPharma Dive553raps253onclive165fda recalls
therapy area
allOncology12999Rare Disease3373Immunology3063Cardiology2865Hematology2328Pulmonology2263Vaccines
  • FDA leadership search continues as lung cancer drug faces rejection and China’s top drugmakers are ranked
    The Readout LOUD podcast this week highlighted three main topics: the FDA’s ongoing search for a new commissioner, a setback for a closely watched lung cancer therapy, and a ranking of China’s bigg…
    STAT · 5h agoRegulatoryNeutral↗ source
  • Bausch + Lomb and Celldex report phase 2 trial failures in atopic dermatitis
    Both Bausch + Lomb and Celldex Therapeutics announced that their recent phase 2 studies did not achieve primary efficacy goals. Celldex’s anti‑KIT antibody barzolvolimab showed no statistically si…
    Fierce Biotech · 12h agoNegative readoutNegative↗ source
← prev
page 1 of 164
next →
122
fda medwatch116
globenewswire health73
fda press62
1882
Psychiatry & CNS1247
Ophthalmology1140
Endocrinology & Metabolism809
Pain801
Nephrology789
  • Big pharma say they will stop opening new trial sites in Xinjiang and Chinese military hospitals
    Several of the world’s largest pharmaceutical companies told a U.S. House Select Committee on China that they will not start new clinical trial sites in the Xinjiang region of China or at hospitals…
    STAT · 15h agoRegulatoryNegative↗ source
  • UnitedHealth sues CMS over lowered 2027 Medicare Advantage star ratings
    UnitedHealth Group has filed a lawsuit against the Centers for Medicare & Medicaid Services seeking to overturn the agency’s lowered star ratings for its Medicare Advantage plans for 2027. The sui…
    STAT · 8h agoRegulatoryNegative↗ source
  • Scientists study blood markers for chronic traumatic encephalopathy using samples from 21 football players
    Researchers collected blood from 21 current football players and arranged for their brains to be donated after death to support chronic traumatic encephalopathy (CTE) research. The team is analyzi…
    STAT · 1h agoNeutral↗ source
  • Exercise should be prescribed alongside rest for concussion recovery, author argues
    The author recounts a severe brain injury that left him in a coma, caused significant muscle loss and left-side weakness, and made simple tasks like getting out of a bathtub a struggle. He began a…
    STAT · 5h agoPositive↗ source
  • Patient coalition urges more agency for participants in brain-implant trials
    A new report released by the BCI Pioneers Coalition outlines 13 recommendations aimed at improving how brain‑computer interface trials are conducted. The guidance targets startups, researchers and…
    STAT · 5h agoNeutral↗ source
  • Only 10% of surgeons in East and Central Africa are women, highlighting gender gap in global surgery
    An opinion piece notes that women comprise just one‑tenth of the surgical workforce across twelve COSECSA member countries, a proportion that has not changed in years. The author observed a documen…
    STAT · 5h agoNegative↗ source
  • CLINUVEL to cut up to 20% of staff and move headquarters to New York
    CLINUVEL announced a strategic reorganization aimed at focusing resources on the U.S. market. The company will reduce its global workforce by 10% to 20%, affecting up to 21 of its 104 employees.…
    BioSpace · 1h agoLayoffsNegative↗ source
  • RevMed pads Rasonque’s first-line survival advantage in pancreatic cancer with early data
    The new data could help boost Revolution Medicines beyond the currently estimated $14.5 billion in peak sales for the recently approved RAS(ON) inhibitor, Truist Securities predicts.
    BioSpace · 36m ago↗ source
  • An Insmed takeout by Sanofi would be ‘clear strategic fit’ in respiratory space
    If it came to fruition, the rumored deal between Sanofi and Insmed would likely be the year’s largest, with one analyst putting a potential value for the biotech as high as $40 billion.
    BioSpace · 43m ago↗ source
  • Merck-Kelun ADC scores survival win in Phase 3 stomach cancer trial
    Licensed from Kelun-Biotech, Merck’s TROP2-targeting antibody drug conjugate sac-TMT improved overall survival in advanced gastroesophageal cancer while missing on two secondary endpoints.
    BioSpace · 55m ago↗ source
  • STAT+: Pharmalittle: We’re reading about Sanofi eyeing Insmed, AI speeding drug development, and more
    Sanofi weighs an Insmed takeover, the FDA slams J&J over misleading bladder cancer drug claims, and more pharma news:
    STAT · 1h ago↗ source
  • STAT+: Early results for Alterome’s KRAS drug for pancreas, lung and colon cancer arrive
    Alterome presented preliminary Phase 1 results of its drug “selectively” targeting a range of KRAS mutations — drivers of cancers in the pancreas, lung and colon:
    STAT · 1h ago↗ source
  • ‘It’s a very healthy sector’: Biopharma gathers in London as M&A shines and China clouds loom
    As the grand hotels and cosy cafes filled with biopharma executives and investors for London Life Sciences Week, the weather was as temperamental as any other English November.
    Fierce Biotech · 8h ago↗ source
  • FDA approves Regeneron's first siRNA therapy for generalized myasthenia gravis
    The FDA has granted approval for Regeneron's siRNA drug Livsayis (cemdisiran) for adult patients with generalized myasthenia gravis who are positive for anti‑acetylcholine receptor antibodies. Thi…
    BioSpace · 1d agoApprovalPositive↗ source
  • Novartis CEO says AI could cut drug development time and boost success rates
    At an investor event in London, Novartis chief executive Vas Narasimhan, who also sits on the board of AI company Anthropic, explained how the Swiss drugmaker is turning to artificial intelligence…
    Fierce Biotech · 22h agoPositive↗ source
  • FDA approves treatments for four rare diseases; Pfizer inks $2.6 billion China licensing deal for CAR‑T therapy
    The U.S. Food and Drug Administration has granted approval for drugs targeting four distinct rare diseases, expanding therapeutic options for patients with limited treatment choices. In a separate…
    raps · 1d agoApprovalPositive↗ source
  • Merck partners with Isomorphic Labs to use AI for discovering oncology drug candidates
    Merck announced a research collaboration with Isomorphic Labs, an artificial‑intelligence drug design firm, to explore small‑molecule candidates aimed at an undisclosed oncology target. Isomorphic…
    STAT · 1d agoDealPositive↗ source
  • Merck teams with Isomorphic Labs to discover new oncology small-molecule candidates
    Merck and Isomorphic Labs announced a research collaboration aimed at discovering small-molecule drugs for an undisclosed oncology target. The partnership will combine Isomorphic’s AI-driven drug…
    STAT · 1d agoDealPositive↗ source
  • Isomorphic Labs partners with Merck on AI-driven oncology drug discovery after $5 billion funding round
    Isomorphic Labs announced a new collaboration with Merck & Co., adding the pharma giant to its AI drug discovery partners. The agreement follows Isomorphic's recent $5 billion financing and will f…
    Fierce Biotech · 1d agoDealPositive↗ source
  • AbbVie signs up to $2.5 B licensing deal with DISCO to develop solid tumor bispecific therapies
    AbbVie announced a licensing agreement with European biotech DISCO Pharmaceuticals that could be worth as much as $2.5 billion. The deal includes a $40 million upfront payment and future milestones…
    BioSpace · 1d agoDealPositive↗ source
  • Novartis CEO says shareholders remain supportive despite recent trial setbacks
    Novartis chief executive Vas Narasimhan told Fierce that, despite a series of recent clinical setbacks, most shareholders continue to back the company’s long-term strategy. The setbacks include th…
    Fierce Biotech · 1d agoPositive↗ source
  • U.S. loses measles elimination status as outbreaks claim first deaths in decades
    The Pan American Health Organization announced that the United States has lost its measles elimination status, a designation it held for 26 years. The decision follows a year‑long period of sustain…
    STAT · 16h agoNegative↗ source
  • Study finds malaria antibody L9LS reduces vaccine response in infants
    Researchers in Mali tested the monoclonal antibody L9LS in infants to see if it could protect against malaria and complement the R21 vaccine. The trial showed L9LS provided about 78% protection ov…
    STAT · 17h agoNegative readoutNegative↗ source